CompletedPhase 2NCT01609790
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Eudocia Q Lee, MDNRG Oncology
- Intervention
- Bevacizumab(biological)
- Enrollment
- 137 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2022
Study locations (30)
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Arizona Oncology-Deer Valley Center, Phoenix, Arizona, United States
- Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
- Arizona Oncology Associates-West Orange Grove, Tucson, Arizona, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Sutter Cancer Research Consortium, Novato, California, United States
- Saint Joseph Hospital - Orange, Orange, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01609790 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC